CMRX Chimerix Inc

Price (delayed)

$2.06

Market cap

$180.12M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.15

Enterprise value

$150.42M

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious ...

Highlights
The debt has plunged by 87% YoY and by 86% from the previous quarter
The EPS has grown by 44% from the previous quarter and by 34% YoY
CMRX's quick ratio is down by 46% year-on-year but it is up by 19% since the previous quarter
The company's gross profit has shrunk by 92% YoY and by 78% QoQ
Chimerix's revenue has plunged by 90% YoY and by 72% from the previous quarter

Key stats

What are the main financial stats of CMRX
Market
Shares outstanding
87.44M
Market cap
$180.12M
Enterprise value
$150.42M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.75
Price to sales (P/S)
320.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
269.08
Earnings
Revenue
$559,000
EBIT
-$100.59M
EBITDA
-$100.15M
Free cash flow
-$85.61M
Per share
EPS
-$1.15
Free cash flow per share
-$0.98
Book value per share
$0.55
Revenue per share
$0.01
TBVPS
$0.75
Balance sheet
Total assets
$65.52M
Total liabilities
$17.72M
Debt
$2.26M
Equity
$47.8M
Working capital
$47.34M
Liquidity
Debt to equity
0.05
Current ratio
4.11
Quick ratio
3.51
Net debt/EBITDA
0.3
Margins
EBITDA margin
-17,915%
Gross margin
79.6%
Net margin
-17,994.3%
Operating margin
-18,017.5%
Efficiency
Return on assets
-90.2%
Return on equity
-118.4%
Return on invested capital
-132.9%
Return on capital employed
-200%
Return on sales
-17,994.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CMRX stock price

How has the Chimerix stock price performed over time
Intraday
13.19%
1 week
32.9%
1 month
13.81%
1 year
-73.45%
YTD
-67.96%
QTD
-55.02%

Financial performance

How have Chimerix's revenue and profit performed over time
Revenue
$559,000
Gross profit
$445,000
Operating income
-$100.72M
Net income
-$100.59M
Gross margin
79.6%
Net margin
-17,994.3%
The net margin has plunged by 106% from the previous quarter
The company's operating margin has shrunk by 106% QoQ
The company's gross profit has shrunk by 92% YoY and by 78% QoQ
Chimerix's revenue has plunged by 90% YoY and by 72% from the previous quarter

Growth

What is Chimerix's growth rate over time

Valuation

What is Chimerix stock price valuation
P/E
N/A
P/B
3.75
P/S
320.94
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
269.08
The EPS has grown by 44% from the previous quarter and by 34% YoY
The equity has dropped by 64% year-on-year and by 30% since the previous quarter
The stock's price to book (P/B) is 46% less than its last 4 quarters average of 6.9 but 39% more than its 5-year quarterly average of 2.7
Chimerix's revenue has plunged by 90% YoY and by 72% from the previous quarter
CMRX's P/S is 2.4% lower than its last 4 quarters average of 329.0

Efficiency

How efficient is Chimerix business performance
The ROS has plunged by 106% from the previous quarter
Chimerix's ROIC has increased by 37% YoY and by 23% from the previous quarter
CMRX's return on assets is up by 30% since the previous quarter and by 24% year-on-year
Chimerix's return on equity has increased by 27% QoQ and by 13% YoY

Dividends

What is CMRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CMRX.

Financial health

How did Chimerix financials performed over time
The total assets has plunged by 59% YoY and by 35% from the previous quarter
CMRX's quick ratio is down by 46% year-on-year but it is up by 19% since the previous quarter
The debt is 95% less than the equity
The debt has plunged by 87% YoY and by 86% from the previous quarter
The debt to equity has shrunk by 79% QoQ and by 62% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.